Type 2 diabetes Trials in Hialeah, United States
Conditions / Type 2 diabetes / Hialeah, United States
Type 2 diabetes is a medical condition with active clinical research programs worldwide.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01195662 | A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication | COMPLETED | PHASE3 |
| NCT02019264 | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | COMPLETED | PHASE4 |
| NCT06972472 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | RECRUITING | PHASE3 |
| NCT00255645 | G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study) | TERMINATED | — |
| NCT07030868 | A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes | TERMINATED | PHASE2 |
| NCT00654745 | 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics | COMPLETED | PHASE4 |
| NCT01137474 | A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker | COMPLETED | PHASE3 |
| NCT01609582 | Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease | TERMINATED | PHASE3 |
| NCT06993792 | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | ACTIVE_NOT_RECRUITING | — |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |